S 4472
A bill to amend the Accelerating Access to Critical Therapies for ALS Act to reauthorize the provisions of such Act through fiscal year 2031, and for other purposes.
Jurisdiction
US Congress
Session
119th Congress (2025-2026)
Last updated at
Jun 16, 2026, 3:01 PM
Take action
Sign in to record your position, submit testimony, or contact your legislator.
Sign in to take action- Introduced
- Passed Senate
- Passed House
- To President
- Became Law
Bill overview
This bill reauthorizes the Accelerating Access to Critical Therapies for ALS Act, extending its provisions through 2031. It makes several key changes to the program, including requiring the Food and Drug Administration to review the status of clinical trials for ALS therapies and updating a report on the agency’s action plan for rare neurodegenerative diseases. The bill also extends the timeframe for the Government Accountability Office’s report on the Act’s effectiveness.
Sponsors
Official sponsors from legislative records.
Primary sponsor
Cosponsor
Arguments in favor
Reasons to support this legislation.
No arguments in favor have been submitted.
Submit yoursArguments opposed
Reasons to oppose this legislation.
No arguments opposed have been submitted.
Submit yoursRead the latest version inline or switch to a previous version.